• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Low Dose Lithium Effective in Bipolar Disorder?

Is Low Dose Lithium Effective in Bipolar Disorder?

February 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Glen Spielmans, PhD Associate professor of psychology, Metropolitan State University, St. Paul, MN Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Subject:
Bipolar Disorder

Short Description:
Is Low Dose Lithium Effective in Bipolar Disorder?

Background:
Although it remains one of our oldest and most effective drugs, lithium has become less popular for the treatment of bipolar disorder in the last two decades. The recent LiTMUS trial compared outcomes in bipolar disorder when all subjects took non-lithium mood-stabilizing medication, while half were also randomized to low-dose lithium. The others remained on their existing medications (“optimized personal treatment,” or OPT) alone. LiTMUS involved 283 subjects with bipolar disorder I (77%) or II. All were considered by their psychiatrists to be candidates for lithium treatment. The lithium group (N=141) was given 600 mg/d lithium for the first two months, with further adjustments up or down as necessary, while the rest remained on OPT alone.After six months of follow-up, the authors found no significant advantage to lithium on the CGI-BP-S (clinical global impression for bipolar severity) scale. Scores decreased by only 1.22 points in subjects in the lithium+OPT group, versus 1.48 points in the OPT group. There was also no difference between the groups in the number of medication adjustments required by clinical need.Was this a failure of lithium? Not necessarily. It’s possible that lithium may simply not have been dosed appropriately. Mean lithium levels in the lithium+OPT group ranged between 0.43 and 0.47 mEq/L during the trial (as opposed to the >0.8 mEq/L recommended by most treatment guidelines). And even though the focus of the trial was on low-dose lithium, clinicians were free to increase lithium dose as much as they wished after the first two months. As a single-blind trial, it is also possible that prescribers may have been reluctant to increase lithium dose for fear of causing additional side effects. Finally, higher doses may only have been given to those subjects with more severe illness.Overall, clinical outcomes were disappointing in both groups, with only one quarter of all subjects achieving remission (defined as CGI-BP-S <2 for two months). Symptomatic improvement ranged from 30% to 50% in both groups. The only metric on which the lithium+OPT group differed from OPT alone was in their lower use of atypical antipsychotics, which were prescribed to only 48.3% of the lithium-OPT subjects (vs. 62.5% of the OPT group) (Nierenberg AA et al, Am J Psychiatry 2013;170(1):102–110).

TCPR’s Take:Lithium has a well-deserved position as a workhorse of modern psychiatry, and while this study’s results seem to call that role into question, a “peek under the hood” shows that lithium may simply have been dosed too conservatively in this study. Notably, only a quarter of all subjects in this naturalistic, “real world” trial achieved remission while taking guideline-driven therapy (OPT), with or without lithium. And while it appears that patients on lithium were less likely to use atypical antipsychotics, it remains an open question whether higher doses of lithium may have produced better clinical outcomes than OPT.
General Psychiatry
KEYWORDS bipolar_disorder
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2013
    SUBSCRIBE NOW
    Table Of Contents
    A Primer on Palliative Care
    Existential Psychotherapies: An Introduction
    The Role of Psychiatry in Palliative Care
    Is Low Dose Lithium Effective in Bipolar Disorder?
    Drugs Acting on Glutamate
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.